Urinary cyclic adenosine 3',5'-monophosphate excretion in children in short stature: effect of somatotropin.
Excretion of urinary cyclic adenosine 3',5'-monophosphate (cAMP) was determined in twenty-four children of short stature and in sixteen normal children. Of the patients, eight suffered from anterior panhypopituitarism, six from isolated deficiency or somatotropin, seven had a family history of short stature, and three had growth failure of pre-natal onset. In children suffering from anterior panhypopituitarism or from isolated somatotropin deficiency, excretion of cAMP was found to be depressed. Short-term administration of purified somatotropin in normal therapeutic dose (3.4 mg per 1.7 m2 i.m. daily for 5 days) had no effect on urinary cAMP, but reduced urine volume in all patient groups. During somatotropin treatment there was a positive correlation between changes in urine volume and nitrogen balance (r = 0.67).
D000293:Adolescent; D001827:Body Height; D002648:Child; D002675:Child, Preschool; D000242:Cyclic AMP / Q000652:urine*; D005260:Female; D006130:Growth Disorders / Q000652:urine*; D013006:Growth Hormone / Q000172:deficiency / Q000494:pharmacology*; D006801:Humans; D008297:Male
D013006:Growth Hormone; D000242:Cyclic AMP